Shares in PTC Therapeutics shot up by as much as 117% to $33.18 on news that its novel treatment for Duchenne muscular dystrophy Translarna (ataluren) has finally received the go-ahead for approval from the EU's CHMP.
Shares in PTC Therapeutics shot up by as much as 117% to $33.18 on news that its novel treatment for Duchenne muscular dystrophy Translarna (ataluren) has finally received the go-ahead for approval from the EU's CHMP.
Reversing an earlier decision, the committee says a conditional approval of the drug is warranted in nonsense mutation DMD patients aged five years and older who are able to walk,...
The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.
The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.
Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.
